285 related articles for article (PubMed ID: 35260095)
21. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
[TBL] [Abstract][Full Text] [Related]
22. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study.
Liu QP; Yang KL; Xu X; Liu XS; Qu JR; Zhang YD
Abdom Radiol (NY); 2022 Feb; 47(2):651-663. PubMed ID: 34918174
[TBL] [Abstract][Full Text] [Related]
23. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
26. A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.
Fang S; Lai L; Zhu J; Zheng L; Xu Y; Chen W; Wu F; Wu X; Chen M; Weng Q; Ji J; Zhao Z; Tu J
Front Mol Biosci; 2021; 8():662366. PubMed ID: 34532340
[No Abstract] [Full Text] [Related]
27. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi M; Akuta N; Okubo S; Matsumura M; Suzuki Y; Hashimoto M
J Gastrointest Surg; 2022 Aug; 26(8):1637-1646. PubMed ID: 35715641
[TBL] [Abstract][Full Text] [Related]
29. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion.
Sheen H; Kim JS; Lee JK; Choi SY; Baek SY; Kim JY
Abdom Radiol (NY); 2021 Jun; 46(6):2839-2849. PubMed ID: 33388805
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
31. [A comparative study of MRI manifestations and pathological changes in hepatocellular carcinoma treated by transcatheter arterial chemoembolization with lipiodol].
Liu R; Wang JH; Zhou KR; Yan FH; Yan ZP; Shen JZ; Tan YS; Cai Y
Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):754-8. PubMed ID: 16248948
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive assessment of response to transcatheter arterial chemoembolization for hepatocellular carcinoma with the deep neural networks-based radiomics nomogram.
Liu Y; Liu Z; Li X; Zhou W; Lin L; Chen X
Acta Radiol; 2024 Jun; 65(6):535-545. PubMed ID: 38489805
[TBL] [Abstract][Full Text] [Related]
33. Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.
Yang X; Yuan C; Zhang Y; Wang Z
Medicine (Baltimore); 2021 May; 100(19):e25838. PubMed ID: 34106622
[TBL] [Abstract][Full Text] [Related]
34. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Interpretability Analysis of Noninvasive Imaging Based on Computed Tomography in Patients with Hepatocellular Carcinoma After Initial Transarterial Chemoembolization.
Dai Y; Liu D; Xin Y; Li Y; Wang D; He B; Zeng X; Li J; Jia F; Jiang H
Acad Radiol; 2023 Sep; 30 Suppl 1():S61-S72. PubMed ID: 37393179
[TBL] [Abstract][Full Text] [Related]
36. Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging.
Peng J; Kang S; Ning Z; Deng H; Shen J; Xu Y; Zhang J; Zhao W; Li X; Gong W; Huang J; Liu L
Eur Radiol; 2020 Jan; 30(1):413-424. PubMed ID: 31332558
[TBL] [Abstract][Full Text] [Related]
37. MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.
Wang Y; Liu Z; Xu H; Yang D; Jiang J; Asayo H; Yang Z
BMC Med Imaging; 2023 May; 23(1):67. PubMed ID: 37254089
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma pathologic grade prediction using radiomics and machine learning models of gadoxetic acid-enhanced MRI: a two-center study.
Han YE; Cho Y; Kim MJ; Park BJ; Sung DJ; Han NY; Sim KC; Park YS; Park BN
Abdom Radiol (NY); 2023 Jan; 48(1):244-256. PubMed ID: 36131163
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
